Concord Biotech Ltd - 543960 - Record Date For Payment Of Final Dividend
Record date for payment of final dividend23-05-2024
23-05-2024
Concord Biotech Ltd - 543960 - Corporate Action-Board approves Dividend
outcome of board meeting held today i.e Thursday may 23, 2024- audited finanical results for the quarter and financial year ended on march 31 202423-05-2024
Concord Biotech Ltd - 543960 - Outcome Of Board Meeting Held Today I.E. Thursday, May 23, 2024- Audited Financial Results For The Quarter And Financial Year Ended On March 31, 2024
Outcome of Board meeting held today i.e thursday may 23,2024- Audited Financial Results for the quarter and financial year ended on March 31, 2024123-05-2024
Concord Biotech Ltd - 543960 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Thursday, May 23, 2024- Audited Financial Results For The Quarter And Financial Year Ended On March 31, 2024
Outcome of Board Meeting held today i.e. Thursday, May 23, 2024- Audited Financial Results for the quarter and Financial Year ended on March 31, 202423-05-2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (LODR) Regulation 2015, as amended from time to time, read with para A of Schedule III thereto, We wish to inform you that the company has arranged Earning Call with Investor/Analyst (Participants) to discuss the standalone and consolidated Financial Results of the Company for the quarter and year ended 31 March 2024 scheduled on Tuesday 28th May, 2024 at 4:00 PM IST. The Earning Call invite is enclosed for your records. Kindly take the same into your records and Oblige21-05-2024
Concord Biotech Ltd - 543960 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. Intimation About Completion Of Inspection By Saudi Food And Drug Authority At Valthera (Unit II) Of The Company
In compliance with the aforesaid regulation, we hereby notify that the Saudi Food and Drug authority has successfully completed inspection of company''s manufacturing Unit II (formulation facility), located at Valthera, Gujarat from tuesday 14th May 2024 to 16th May, 2024. Kindly take the above information on record.17-05-2024
Concord Biotech Ltd - 543960 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday, May 23, 2024 Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2024 ,inter alia, to consider and approve 1. Consider and approve the Standalone and Consolidated Audited Financial Results for the Fourth quarter and Year ended March 31, 2024 2. To consider other business matters along with Recommendation of Dividend, if any. 3. Any other Business Further, in continuation of our earlier letter dated April 01, 2024 under subject 'Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company''s Code of Conduct to Regulate, Monitor and Report trading by Designated Persons and their immediate relative, the trading window for dealing in the securities of the Company shall remain closed up to 48 hours after the declaration of the Financial Results of the Company for the fourth quarter and Financial Year ended March 31, 2024. You are requested to take the same on record.15-05-2024
Concord Biotech Ltd - 543960 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyConcord Biotech Ltd 2CIN NO.U24230GJ1984PLC007440 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 6.23 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Prakash Sajnani Designation: Asst Vice president Finance and CS EmailId: [email protected] Name of the Chief Financial Officer: Lalit Sethi Designation: Chief Financial Officer EmailId: [email protected] Date: 25/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.25-04-2024
Concord Biotech Ltd - 543960 - Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015 For The Year Ended On 31St March, 2024
Pursuant to regulation 7(3) of SEBI (LODR)Regulation, 2015, as amended from time to time, we hereby confirm that all activities in relation to both physical and electronic share transfer facility during the period from 01.04.2023 to 31.03.2024 (both days inclusive) are maintained by the Company''s Registrar & Share Transfer Agent viz., Link Intime India Private Limited, which is registered as Registrar and Share Transfer Agent in Category-I with SEBI via Registration No. INR000004058. Kindly take the same on record.18-04-2024